METHODS:
Severely obese and lean control subjects are examined at enrollment and at subsequent annual visits by using detailed questionnaires, anthropometric measurements, indirect calorimetry, and functional tests such as oral glucose tolerance tests. Some subjects undergo additional characterization with MRI, subcutaneous fat biopsies, frequent blood sampling, and hyperglycemic clamps. Biological samples are obtained and stored in a biobank.
RESULTS: Active recruitment started in 2010, and standard operating procedures have been established. A high participation rate and annual follow-ups have resulted in a cohort exceeding 200 subjects, including 45 lean controls (as of October 2013). Initial research focus has been on traits of the metabolic syndrome, hyperinsulinemia and identifying risk factors for type 2 diabetes.
CONCLUSIONS:
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The worldwide prevalence of obesity was estimated at approximately half a billion afflicted individuals in 2008 and is expected to exceed 1 billion individuals in 2030. 1, 2 The cause of obesity is multifactorial, for which genetics, environment, socioeconomic status, culture, and ethnicity are some primary factors. 3, 4 Thus, the pathophysiology of obesity is a result of a complex interaction between environmental and genetic factors 5, 6 that still are not fully delineated and understood. Obesity is defined as a body mass index (BMI) $30 and overweight as a BMI $25 in adults. 2 In children, BMI is adjusted for age and gender. 7, 8 Obesity is related to increased risk of morbidity and mortality. In a recent report by the World Health Organization (WHO), obesity and overweight were estimated to account for 44% of health problems related to type 2 diabetes mellitus (T2DM), 23% of health problems related to ischemic heart disease, and 7% to 41% of health problems related to certain forms of cancer. 2 Particularly concerning is that the number of children suffering from obesity has increased worldwide, 9 with extensive consequences for national and international health and related health care budgets. 10 Childhood obesity is the focus of the WHO Childhood Obesity Surveillance Initiative, which recently reported a prevalence between 6% and 12% in the European region. 11 In the same report, the prevalence of overweight children was between 19% and 28%. The Centers for Disease Control and Prevention have published numbers for obesity rates in the United States. For children and adolescents aged 2 to 19 years, the prevalence of obesity was as high as 17%. 12 Whereas the percentages in the WHO study were obtained by using the standard WHO criteria for overweight and obesity, 8 the Centers for Disease Control and Prevention' s 2000 growth charts were used in the latter study. 13 In Sweden, the percentages for obese and overweight children in the WHO report were 6% and 23%, respectively. 11 The latter percentages reflect a substantial increase in the number of Swedish children suffering from obesity or overweight during recent decades. Indeed, the tendency in Sweden, especially among young girls, is that the average age-adjusted BMI of children tends to increase over time. 14 In response to the increasing prevalence of childhood obesity, the pediatric obesity clinic at the Uppsala University Children' s Hospital was established in 2008. The clinic functions as a regional referral center for children with severe obesity. Its main objective is to help patients with severe obesity and, in close collaboration with the patients' families, find ways to improve their health, where weight reduction is a cornerstone. In this task, which is carried out by a multidisciplinary team, gathering information about the patients, including both medical history and results from various examinations is fundamental. At the clinic, not only routine clinical work is being carried out but also extensive research on childhood obesity. Children and their legal guardians are asked if they wish to take part in the current research study, aiming to create a better understanding of underlying causes and mechanisms in development of childhood obesity and related diseases, in particular T2DM. Those who wish to take part are recruited into the Uppsala Longitudinal Study of Childhood Obesity (ULSCO) cohort, which was initiated in 2010.
The aim of this article is to present the protocol description used in ULSCO characterization, provide some baseline data, and indicate research topics that are addressed by the cohort. The main research areas of the childhood obesity cohort include: 
METHODS

Subject Enrollment
Children #18 years old with severe obesity (age-adjusted BMI $35) in Uppsala and surrounding regions who have been referred to the pediatric obesity clinic at Uppsala University Children' s Hospital are eligible for enrollment into ULSCO. Lean (ageadjusted BMI ,25) healthy age-and gender-matched control children are enrolled through collaboration between Uppsala University and local schools in the Uppsala area as well as through advertisement. Parents and siblings of subjects are also asked to be included for genetic analysis. At enrollment, the project is described to the subject and legal guardians and informed consent is obtained. Inclusion criteria are primarily based on ageadjusted BMI. Exclusion criteria include serious psychiatric disorders, and severe diseases, such as malignancies.
Protocols
The procedures, including clinical assessments, examinations, and questionnaires (Table 1) , are conducted at enrollment and at annual follow-up visits (Fig 1) . These procedures are also conducted in lean subjects. Special attention is given to examinations addressing body composition, metabolism, and hormones regulating nutrient handling during an oral glucose tolerance test (OGTT) or ARTICLE prolonged glucose challenge with intravenous hyperglycemic clamp.
Blood Sampling
All examination procedures, including sample collection and storage, are conducted according to established standard operating procedures. A nurse conducts the blood sampling from a peripheral vein. Local anesthesia with Eutectic Mixture of Local Anesthetics (EMLA) (AstraZeneca AB, Södertälje, Sweden) is offered to subjects before venipuncture. Blood volumes drawn are calculated on the basis of the subject's age and weight. Research samples are collected by using both EDTA and P800 (BD AB, Stockholm, Sweden) tubes. Samples are immediately placed on ice and centrifuged at 2500 3 g for 10
FIGURE 1
Time chart of visits by subjects at the pediatric obesity clinic and specified times when assessments and examinations are conducted within the ULSCO cohort. Red arrowheads indicate a potential new treatment strategy and/or research focus. minutes in a +4°C centrifuge. Plasma is then separated into aliquots and stored in a local 270°C freezer within 1 hour of sampling. In addition, selected samples are immediately taken to the laboratory for analyses, and some samples are stored as whole blood for DNA analyses (Table 2) .
OGTT
OGTT is performed in subjects after an overnight fasting period of at least 10 hours. Instructions are given to avoid major changes in dietary habits and physical exercise levels during at least 3 days before the examination. After obtaining fasting blood samples, the subject is instructed to drink a glucose solution of 1.75 g glucose/kg bodyweight (maximum 75 g) mixed carefully in ∼300 mL of water. Additional blood samples are obtained by using EDTA and P800 tubes at specified intervals of time. For routine OGTT the time points are 5, 10, 15, 30, 60, 90, and 120 minutes (Table 1 ). In some subjects, an extended OGTT is performed, with sampling at 180 minutes. Frequent blood sampling is performed in selected subjects to investigate the dynamics of insulin secretion. Small amounts of blood are sampled with 1-to 2-minute intervals in fasting state. In subjects $10 years old, hyperglycemic and hyperinsulinemic clamps are performed in a subgroup of subjects.
Body Composition
Waist circumference is measured with a flexible tape midway between the superior border of the iliac crest and the lowest rib on a standing subject, and hip circumference at the greatest circumference of the hip (Table 1) . 15 Skinfold thickness is measured by using a Harpenden skinfold caliper (Baty International, Burgess Hill, West Sussex, UK) on the following sites (duplicate measurements at each site): triceps, biceps, subscapularis, and suprailiac. Body composition is calculated by bioimpedance using an InBody S20 bioimpedance device (Biospace, Seoul, Korea) on a fasting subject who is instructed to empty the bladder before the examination. Additional estimation of body composition is acquired by air displacement plethysmography, using a Bodpod 1-800-4 (LMI-Life Measurement, Inc, Concord, CA). Magnetic resonance imaging (MRI), using a 1.5-T clinical scanner (Achieva; Philips Healthcare, Best, The Netherlands), is conducted in subjects $10 years of age ( Table 1 
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; FSH, follicle-stimulating hormone; g-GT, g-glutamyl transpeptidase; GH, growth hormone; GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; Ig, immunoglobulin; IGF-1, insulin-like growth factor 1; LDL, low-density lipoprotein; LH, luteinizing hormone; NEFA, nonesterified fatty acid; PAI-1, plasminogen activator inhibitor 1; SHBG, sex hormone binding globulin; TNF, tumor necrosis factor; TSH, thyroid-stimulating hormone.
-, parameters not measured.
ARTICLE
Questionnaires
All subjects and legal guardians answer questionnaires, which include questions about medical history, nutrition, physical activity, well-being, stress, relationships/ networks, and goals (Fig 2) . The questionnaires also include screening questions for sleeping habits as well as attention-deficit/hyperactivity disorder.
Biobank
Blood samples in the fasting state as well as during a glucose challenge are obtained from both severely obese and lean subjects ( Table 1 ). All collected biological samples, which are not analyzed immediately, are stored in a centralized biobank (Uppsala Biobank registration number 822). Storage of samples is carefully monitored with information about freeze-thaw cycles, hemolysis, and aliquot volumes. The biobank is located at Uppsala University and contains 270°C freezers with a centralized alarm and access to backup freezers.
Ethical Considerations
Conducting clinical research on children raises several ethical questions, 17 which include considerations regarding safety, discomfort during examinations, benefitrisk assessment, etc. The protocols and examinations performed within the ULSCO cohort have been approved by the Uppsala Regional Ethics Committee (registration numbers 2010/036 and 2012/318). Before enrollment, informed and written consent is obtained from legal guardians. For subjects $12 years of age, written consent is also obtained from the subjects themselves. Participation in the cohort is voluntary, and consent can be withdrawn at any time by subjects and legal guardians without having to state a reason.
Calculations of Glucose Tolerance and Metabolic Syndrome
The WHO criteria for diabetes, impaired glucose tolerance, impaired fasting glucose, and normoglycemia were used for individuals who underwent a 2-hour OGTT. 18 The metabolic syndrome was evaluated on the basis of the International Diabetes Federation' s criteria for pediatric populations. 19 
Statistical Analyses
Power calculations are performed to determine the required sample size before each study, using material from the cohort. Comparisons between groups are performed by using ANOVA and Student's t tests or nonparametric tests. Linear regression models are used to assess correlations between various parameters. Statistical analyses are currently conducted by using GraphPad Prism 6.0c (GraphPad Software, Inc, La Jolla, CA). P values ,.05 are considered statistically significant.
RESULTS
The ULSCO pediatric cohort was established in 2010 and serves as a large longitudinal study, continuously recruiting children with severe obesity as well as lean age-and gender-matched control subjects. Currently (as of October 2013), the cohort contains data and biological samples from 208 subjects (97 girls and 111 boys). One hundred sixty-three subjects are severely obese, and 45 subjects serve as lean controls. Subjects with severe obesity are enrolled during visits to the pediatric obesity clinic. At the visits, lifestylerelated issues are addressed (Fig 2) , examinations conducted (Table 1) , and parameters determined (Table 2) by a multidisciplinary team consisting of pediatricians, nurses, psychologists, dieticians, epidemiologists, radiologists, and basic scientists. Whereas the age at enrollment of severely obese subjects varies between 3 to 18 years, the ages of the lean subjects are currently between 6 and 17 years (Fig 3) . Annual follow-up visits of the severely obese and lean subjects are a crucial part of ULSCO (Fig 1) . Currently, .100 annual follow-up examinations have been conducted, most of them during the 2012 and 2013 (Fig 4) . For some subjects, 3-year time-series data sets have been obtained and are currently being analyzed.
FIGURE 2
Areas covered by the ULSCO cohort questionnaires that address factors contributing to development of obesity.
a Includes determining the psychological and psychiatric status of the subject.
FIGURE 3
Age at enrollment of severely obese (black bars) and lean (white bars) subjects into the ULSCO cohort.
Initially, the subjects of the ULSCO cohort were characterized with regard to glucose tolerance and manifestations of the metabolic syndrome. In the current cohort, ∼54% of the severely obese subjects are normoglycemic, approximately 4% suffer from T2DM, whereas the remaining subjects are in a glycemic state of prediabetes with impaired glucose tolerance or impaired fasting glucose. Among lean subjects, 1 subject has impaired glucose tolerance, whereas all others are characterized as normoglycemic. The metabolic syndrome, as defined by the International Diabetes Federation, is present in 34% of the subjects .10 years of age with severe obesity. None of the lean subjects suffers from the metabolic syndrome. Furthermore, severely obese children display fasting hyperinsulinemia amounting to an ∼3.5-fold increase compared to lean subjects. Preliminary results from MRI data indicate large differences in subcutaneous adipose tissue, visceral adipose tissue, and liver fat measurements between severely obese and lean subjects, as well as within the group of severely obese subjects (Fig 5) .
DISCUSSION
The ULSCO cohort was initiated to increase the knowledgeandunderstanding of early causes of childhood obesity and obesity-related diseases. Within the study, clinical information is gathered and systematized and biological samples are collected and stored in a biobank. The ULSCO cohort therefore constitutes a significant resource when addressing questions related to childhood obesity and diseases associated with obesity, including the areas of metabolism, cardiovascular disease, endocrinology, and neuropsychiatry.
In the cohort, approximately every third severely obese subject .10 years of age suffers from the metabolic syndrome, which is comparable to numbers obtained in other countries. 3 In addition, many subjects have impaired glucose tolerance and some have already developed overt T2DM in their adolescent years. T2DM was previously a disease of the elderly, but due to the current increase in childhood obesity, guidelines and recommendations for treatment of T2DM in adolescents have been established 20 and are currently implemented around the world. Children with obesity are at increased risk of adult obesity, 21 stressing the importance of increased knowledge and effective measures of early interventions.
ULSCO subjects are enrolled at an early age. This approach allows us to study initial metabolic events that trigger metabolic disorder and disease development, when compensatory biological mechanisms are less significant. In addition, most of the subjects are drugnaive, which makes it easier to evaluate underlying pathophysiologic mechanisms. These conditions render the cohort valueinidentifyingfactorsimplicated in obesity and related disease processes.
The design of ULSCO, especially the aspect of storing biological samples from carefully phenotyped subjects in a biobank, opens possibilities for multiple future studies. Indeed, ULSCO is already contributing to a larger translational research initiative, where results from the cohort are further evaluated mechanistically in national and international collaborative efforts. An important aspect of ULSCO is that it enrolls healthy lean subjects. The scarcity of reference data in the pediatric population makes the characterization of normal-weight children
FIGURE 4
Total number of subjects (black bars), number of newly enrolled subjects (gray bars), and number of subjects attending annual follow-ups (white bars) in the ULSCO cohort during the period 2010-2013.
FIGURE 5
Example of MRI data from the abdominal adipose tissue volumetric scan from three 13-year-old boys. One lean (left) and 2 severely obese (middle and right) subjects. The imaging protocol maps absolute fat content from 0% (black) to 100% (white). These examples show large differences in subcutaneous and intraabdominal (visceral) adipose tissue volumes as well as liver fat infiltration. Childhood obesity has become a serious health threat, with patients at increased risk of future morbidity and mortality. 22 Therefore, childhood obesity is addressed in several cohorts such as the Danish National Birth Registry, 23 the Avon Longitudinal Study of Parents and Children, 24 the Leipzig Research Centre for Civilization Diseases (LIFE) Child Study, 25 and the Millennium Study Cohort. 26 These initiatives have different emphases with regard to geographic and ethnic variations, which have been documented as important determinants in obesity development. 27 In this respect to ethnic and geographic considerations, the ULSCO cohort represents an important contribution. Furthermore, the ULSCO cohort has adopted strict procedures for enrollment, characterization, sampling and examination. Therefore, results from ULSCO can be merged in larger study initiatives and collaborations with similar standard operating procedures. Such mergers of results allow complex issues to be investigated, where meta-analysis of large numbers of children often is required. Indeed, with large cohorts in different regions of the world, issues such as genetics and environmental factors in development of obesity and subsequent disease progression can better be addressed. 28 In addition and importantly, the ULSCO cohort has focused on extensive and careful characterization and phenotyping of the subjects at enrollment and annual follow-up visits. Highly specialized assessments and examinations, including MRI, frequent blood sampling and subcutaneous adipose biopsies, are important parts of the characterization.
CONCLUSIONS
The ULSCO pediatric cohort enrolls both severely obese and lean children. Subjects of the cohort are examined and characterized at multiple, consecutive visits, when biological samples are obtained and stored. Through the ULSCO initiative detailed high-resolved time-series data and samples are available, which generate opportunities to study disease progression. Indeed, one objective of the ULSCO cohort is to identify risk factors of future disease in children with severe obesity. Identification of such risk factors is expected to contribute to defining and understanding mechanisms involved in development of both childhood obesity and related diseases. The knowledge generated is expected to allow us to define novel genetic, environmental and metabolic mechanisms associated with childhood obesity.
